subscribeSubscribe
Biogen`s rare genetic disorder drug gets approval in EU

Biogen`s rare genetic disorder drug gets approval in EU
FIERCE PHARMA
13 Feb 2024
Share Share
Biogen`s Skyclarys backed by EU panel for Friedreich`s ataxia

Biogen`s Skyclarys backed by EU panel for Friedreich`s ataxia
GLOBENEWSWIRE
16 Dec 2023
Share Share
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio

Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
HEALTH ET
29 Jul 2023
Share Share
Biogen to Acquire Reata Pharmaceuticals

Biogen to Acquire Reata Pharmaceuticals
GLOBENEWSWIRE
28 Jul 2023
Share Share
Plano-based Reata Pharmaceuticals launches its first drug, Skyclarys

Plano-based Reata Pharmaceuticals launches its first drug, Skyclarys
DALLASNEWS
29 Jun 2023
Share Share
Reata Pharma Announces Approval of Prior Approval Supplement for SKYCLARY

Reata Pharma Announces Approval of Prior Approval Supplement for SKYCLARY
BUSINESSWIRE
27 Jun 2023
Share Share
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS®

Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS®
BUSINESSWIRE
15 Jun 2023
Share Share
FDA signs off on Reata`s Skyclarys for rare neurologic disorder

FDA signs off on Reata`s Skyclarys for rare neurologic disorder
Kevin Dunleavy FIERCE PHARMA
02 Mar 2023
Share Share
Reata has wait for FDA ataxia drug decision delayed by 3 months

Reata has wait for FDA ataxia drug decision delayed by 3 months
James Waldron FIERCEBIOTECH
10 Aug 2022
Share Share
Karuna`s schizophrenia drug passes PhIII test, will head to FDA in mid-2023

Karuna`s schizophrenia drug passes PhIII test, will head to FDA in mid-2023
Tyler Patchen ENDPTS
09 Aug 2022
Share Share